Hamilton Thorne Ltd. announced the appointment, of Dr. Ekaterina (Kate) Torchilin as its new President and Chief Executive Officer, effective January 15, 2024. Dr. Torchilin is succeeding David Wolf, who is retiring as President and CEO. Mr. Wolf will continue to serve the company as Executive Chairman.

Dr. Torchilin will also join the Hamilton Thorne Board of Directors upon assuming the CEO role. Dr. Torchilin is currently the President of the Biologicals and Chemicals Division at Thermo Fisher Scientific, where is she is responsible for the development, manufacture, and global commercialization of the cell culture, cell therapy and chemical business that supports the manufacturing of vaccines and biologics therapies. Dr. Torchilin began her career at Thermo Fisher supporting strategic mergers and acquisitions in their Life Sciences Group and has successfully progressed through a series of operational and general management roles at continually larger businesses, including serving as Vice President and General Manager of their Purification and Pharma Analytics business and Vice President and General Manager of their Cell Culture and Cell Therapy business.

Dr. Torchilin also has over 20 years of experience in the life sciences and healthcare industries, including, serving as Global Head of Connected Health and Women's Health at Alere Inc., where she was responsible for their global business in diagnostic testing supporting healthy pregnancy. Dr. Torchilin earned a PhD. in biochemistry from Tufts University and an MBA from Harvard Business School.

As Executive Chairman, Mr. Wolf will provide leadership and management to the Company?s board of directors and support Kate in her transition. He will also continue to work actively to develop acquisition initiatives and strategic stakeholder and industry relationships.